CryoPort Inc. Common Stock (CYRX)
Stock · NASDAQ · Health Care
$16.85as of 10/16/2026
Price chart
Active signals
CYRX Signal Track Record
How signals performed across all stocks →What CYRX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 32 | +1.3% | 59% | September 8, 2026 |
| Bollinger Band Breakout | 27 | -0.3% | 48% | September 21, 2026 |
| Bollinger Band Breakdown | 17 | +10.7% | 65% | March 10, 2026 |
| 200-Day Moving Average TouchActive now | 8 | -6.6% | 25% | March 4, 2026 |
| Any 20-session window (baseline) | +0.3% | 51% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CYRX
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide. The company's Life Sciences Services segment provides temperature-controlled logistics and biostorage, bioservices and cryopreservation services within the life science industry. Its Life Sciences Products segment manufactures, and sells cryogenic freezers, cryogenic d…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 684
- Website
- www.cryoport.com/
Fundamentals
- 1-day range
- $16.66$17.14
- Market cap
- $741.42M
- P/E (trailing)
- —
- P/E (forward)
- -25.39
- EPS (trailing)
- $-0.75
- Dividend yield
- —
- Beta
- 1.88
- Avg. volume
- 629.8K
How CryoPort Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 5, 2026 · via SEC EDGAR / Finnhub
Forecasts
9 analyst ratings
CryoPort Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- CYRXCryoPort Inc. Common Stock$16.84▼ 1.35%Market cap $741.42MP/E —$7.61$18.36
- CTMXCytomX Therapeutics Inc. Common Stock$2.28▼ 5.39%Market cap $733.66MP/E —$2.2$8.21
- RIGLRigel Pharmaceuticals Inc. Common Stock$45.97▼ 2.71%Market cap $732.62MP/E 2.76$24.95$52.24
- OCSOculis Holding AG Ordinary shares$7.29▼ 1.49%Market cap $717.85MP/E —$7.11$34.48
- PHARPharming Group N.V. ADS each representing 10 ordinary shares$9.36▼ 2.80%Market cap $766.28MP/E 73.41$0.8338$1.82
- GYREGyre Therapeutics Inc. Common Stock$6.08▼ 5.00%Market cap $713.53MP/E —$5.44$9.42
- BBOTBridgeBio Oncology Therapeutics Inc. Common Stock$2.82▼ 4.41%Market cap $703.34MP/E —$3.79$14.87
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CYRX CryoPort Inc. Common Stock | $741.42M | — | $16.84 | ▼ 1.35% | $7.61$18.36 |
| CTMX CytomX Therapeutics Inc. Common Stock | $733.66M | — | $2.28 | ▼ 5.39% | $2.2$8.21 |
| RIGL Rigel Pharmaceuticals Inc. Common Stock | $732.62M | 2.76 | $45.97 | ▼ 2.71% | $24.95$52.24 |
| OCS Oculis Holding AG Ordinary shares | $717.85M | — | $7.29 | ▼ 1.49% | $7.11$34.48 |
| PHAR Pharming Group N.V. ADS each representing 10 ordinary shares | $766.28M | 73.41 | $9.36 | ▼ 2.80% | $0.8338$1.82 |
| GYRE Gyre Therapeutics Inc. Common Stock | $713.53M | — | $6.08 | ▼ 5.00% | $5.44$9.42 |
| BBOT BridgeBio Oncology Therapeutics Inc. Common Stock | $703.34M | — | $2.82 | ▼ 4.41% | $3.79$14.87 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- CryoPort Q2 2026 Earnings Call Transcriptbenzinga · 10/13/2026
- Is CryoPort (CYRX) Outperforming Other Medical Stocks This Year?Yahoo · 10/1/2026
- Guggenheim Maintains Buy on CryoPort, Raises Price Target to $19Benzinga · 10/1/2026
- Cryoport: Strong Pipeline Of Cell And Gene Therapy ApprovalsSeekingAlpha · 9/25/2026
- BTIG Reiterates Buy on CryoPort, Maintains $25 Price TargetBenzinga · 9/18/2026
Insider Activity
Insider Actions →- SHELTON JERRELL · August 11, 2026 · Sale28.8K @ $14.91
- ZECCHINI EDWARD J · June 11, 2026 · Option Exercise33.6K @ $4.8
- ZECCHINI EDWARD J · June 11, 2026 · Sale33.6K @ $14.47
- ZECCHINI EDWARD J · June 10, 2026 · Option Exercise1.4K @ $4.8
- ZECCHINI EDWARD J · June 10, 2026 · Sale1.4K @ $15.23
- Mandalam Ramkumar · June 8, 2026 · Sale23.2K @ $15.44
- Linda Baddour · June 5, 2026 · Grant16.1K
- Linda Baddour · June 5, 2026 · Grant10.3K
- Robert J. Hariri · June 5, 2026 · Grant10.3K
- Mandalam Ramkumar · June 5, 2026 · Grant16.1K
- HANCOCK DANIEL M · June 5, 2026 · Grant16.1K
- HANCOCK DANIEL M · June 5, 2026 · Grant10.3K
- Robert J. Hariri · June 5, 2026 · Grant16.1K
- Mandalam Ramkumar · June 5, 2026 · Grant10.3K
- STEFANOVICH ROBERT · June 4, 2026 · Sale169.4K @ $16.27
Institutional Ownership
March 31, 2026
- Total shares held
- 46.80M
- Total value held
- $375.69M
- Institutional holders
- 162
- Unknown4.78M
- Unknown4.58M
- Unknown3.98M
- Unknown2.97M
- Unknown2.12M
- Unknown1.70M
- Unknown1.50M
- Unknown1.42M
- Unknown1.25M
- Unknown1.16M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
BTIG Keeps CryoPort Target at $25 Amid Cell Therapy Pipeline
BTIG reiterated its positive stance on CryoPort, maintaining a $25 price target. This follows commentary highlighting the company's strong pipeline of cell and gene therapy approvals. The stock is currently trading near the upper end of its 52-week range, reflecting recent momentum in the sector.
BTIG Keeps CryoPort Target at $25 Amid Cell Therapy Pipeline. BTIG reiterated its positive stance on CryoPort, maintaining a $25 price target. This follows commentary highlighting the company's strong pipeline of cell and gene therapy approvals. The stock is currently trading near the upper end of its 52-week range, reflecting recent momentum in the sector.